Antidepressant prescribing trends for adults with and without autism in the United Kingdom from 1997 to 2023, a population-based cohort study using Clinical Practice Research Datalink Aurum
Sadik, A.; Khandaker, G. M.; Pardinas, A. F.; Lundberg, M.; Lee, B. K.; Magnusson, C.; Rai, D.; Madley-Dowd, P.
Show abstract
BackgroundAntidepressant prescribing and autism diagnoses have both increased in recent years, however antidepressant prescribing patterns for autistic adults are not well understood. Aims: (1) To describe antidepressant trends in autistic and non-autistic adults in the UK from 1997 to 2023. (2) To compare trends between autistic adults and age- and sex-matched non-autistic adults. (3) To investigate how trends vary by intellectual disability (ID) status, age-group and sex. MethodsUsing population-representative primary care records from the Clinical Practice Research Datalink Aurum, we defined three autistic groups - autistic adults with ID, autistic adults without ID and all autistic adults - and four non-autistic groups - all non-autistic adults and an age- and sex-matched comparator group for each autistic group. In each calendar year we calculated: annual, lifetime and new antidepressant prescribing; indications for serotonin-selective reuptake inhibitor initiation; average doses prescribed for citalopram, fluoxetine, and sertraline; and the proportion of courses that lasted over 1, 2 and 3 years. We performed primary analyses in 16-64 year olds and repeated them with stratification by sex and age-group. ResultsIn all, 34,173,295 non-autistic adults and 172,242 autistic adults were included (47,011 with ID and 125,231 without ID). 30% of autistic adults and 14.7% of non-autistic adults were prescribed an antidepressant in 2023. Annual prescribing, average doses and course durations increased for all groups during the study period, and were higher for autistic adults than non-autistic adults. Annual, new and lifetime prescribing were highest in autistic adults without ID, whereas course durations were highest in autistic adults with ID. Recording of depression and anxiety as indications was lower for those with ID. Trends were largely similar across sex and age strata, with higher prescribing among females. ConclusionsAntidepressant prescribing for autistic adults has increased since 1997 and patterns of use vary by intellectual disability status.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Whole-genome sequencing analysis of clozapine-induced myocarditis 90%
- Investigating an in-silico approach for prioritizing antidepressant drug prescription based on drug-induced expression profiles and predicted gene expression 89%
- Transcriptional analysis of sodium valproate in a serotonergic cell line reveals gene regulation through both HDAC inhibition-dependent and independent mechanisms 87%
Similar papers in this journal
- Antipsychotic management in general practice: serial cross-sectional study (2011-2020) 96%
- Preconception indicators and associations with health outcomes reported in UK routine primary care data: a systematic review 87%
- Trends and variation in unsafe prescribing of methotrexate: a cohort study in English NHS primary care. 87%
Similar papers in this journal
- Genetic predisposition to psychiatric disorders and risk of COVID-19 91%
- Efficacy and safety of esketamine for treatment resistant depression: registered report for a Systematic Review with an Individual Patient Data Meta-analysis of Randomized, Double-Blind, Placebo-Controlled Trials 90%
- How important are parents in the development of child anxiety and depression? A genomic analysis of parent-offspring trios in the Norwegian Mother Father and Child Cohort Study (MoBa) 89%
Similar papers in this journal
- Rare but elevated incidence of hematological malignancy after clozapine use in schizophrenia: a population cohort study 92%
- Clinical benefits of modifying the evening light environment in an acute psychiatric unit: A single-centre, two-arm, parallel-group, pragmatic effectiveness randomised controlled trial 91%
- Identifying Potential Causal Risk Factors for Self-Harm: A Polygenic Risk Scoring and Mendelian Randomisation Approach 90%
Similar papers in this journal
- Elevated brain-derived cell-free DNA among patients with first psychotic episode - a proof-of-concept study 88%
- Systematic analysis of electronic health records identifies drugs reducing risk of COVID-19 hospitalization and severity 88%
- Associations of proton pump inhibitors with susceptibility to influenza, pneumonia, and COVID-19: Evidence from a large population based cohort study 88%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.